Abstract: The present invention relates to novel substituted steroid derivatives which represent selective inhibitors of the 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration.

Abstract: A topical formulation of an androstane steroid compound of improved solubility in combinations of the solvents propylene glycol and propylene carbonate.

Abstract: Polymers comprising repeating units of the formula I where the variables are defined as follows: a is an integer from 0 to 3, R1, R2, R3 are identical or different and are selected independently from among hydrogen, C1-C20-alkyl, C1-C20-alkyl containing one or more Si, N, P, O or S atoms, C6-C30-aryl, preferably C6-C14-aryl, C4-C14-heteroaryl, —N(C6-C14-aryl)2, and Y1, where Y1 may be identical or different and are selected from among —CH?CH2, trans- or cis-CH?CH—C6H5, acryloyl, methacryloyl, methylstyryl, O—CH?CH2 and glycidyl, where Y2 is selected from among —CH?CH2, trans- or cis-CH?CH—C6H5, acryloyl, methacryloyl, methylstyryl, —O—CH?CH2 and glycidyl, and one or more groups Y1 or Y2 may be crosslinked to one another.

Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and haematological malignancies. Further the conjugates exhibits a synergistic action together with a cytoskeleton acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non responsive to Taxol®.

Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and hematological malignancies. Further the conjugates exhibit a synergistic action together with a cytoskeleton-acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non-responsive to Taxol®.

Abstract: The invention pertains to a process for the preparation of a high purity composition of (7?, 17?)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5% of (7?, 17?)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one. This composition can be used as a source for the preparation of stable pharmaceutical dosage units.

Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: and HO-antibody-spacer-(A2)n and, in particular, betulinol dimethyl ether. Methods for making and using these derivatives and conjugates, as well as a method for making and using betulonic aldehyde, are also disclosed.

Abstract: The present invention relates to, for example, a compound of formula (VIII) 1

Abstract: The invention relates to a pharmaceutical composition for the treatment of psoriasis and other skin diseases. The inventive composition comprises 17-clobetasol propionate and a hydroxyl derivative of progesterone having formula (I) wherein: R6 denotes H or methyl; R11 denotes H or hydroxyl; and R17 denotes H or hydroxyl, but R11 and R17 cannot be H simultaneously. Preferably, said composition is administered as a lotion with: 0.05-2% 17-clobetasol propionate; 0.3-1% of (I); a solvent selected from among ethanol, isopropanol and mixtures thereof; 40% cosolvent selected from among propylene glycol, glycerine, sorbitol and mixtures thereof; and 20% water. In the ideal lotion, the solvent is ethanol and the cosolvents are approximately: 35% propylene glycol, 5% glycerine and 20% water. The invention affords the following advantages: longer interval between recurrences and fewer local secondary effects. Moreover, the inventive composition can be used for the treatment of psoriasis.

Abstract: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

Abstract: The process for making steroid crystals having a predetermined average particle size in a predetermined size range and a maximum particle size that does not exceed a predetermined maximum value, includes subjecting a supersaturated solution containing a steroid to a wet milling by a wet milling apparatus while crystallizing, in order to obtain a primary particle suspension. Crystals obtained according to this process and pharmaceutical preparations containing them are also described.

Abstract: A novel action mechanism wherein androgen receptor (AR) is activated by the interaction between cyclin E and the androgen receptor was revealed. This activation is resistant to existing anti-androgen agents and both androgen receptor ligand-dependent and independent activations were found to participate in this mechanism. Methods of screening for anti-androgen agents using cyclin E are also provided by the present invention. Based on the findings as described above, novel anti-androgen agents can be screened. These anti-androgen agents are expected to be efficacious also against pathological conditions that have become resistant to existing anti-androgen agents. Thus, the instant invention opens up new possibilities for treatment using anti-androgen agents that had their limitations until now.

Abstract: The invention concerns the use of steroids and non-toxic compounds, capable of crossing the blood brain barrier characterised in that they are capable of binding the same site as pregnenolone on proteins constituting or associated with elements of the cytoskeleton and of displacing the MAP-bound pregnenolone, and of influencing the assembling and stabilisation of microtubules The invention is particularly useful for treating the nervous system, for fighting against ageing of cells containing MAPs, and for treating cancers.

Abstract: This Invention refers to the use of molecularly imprinted polymers as a method in which the selectivities of imprinted materials can be gainfully employed as binding matrices in the screening of combinatorial libraries.

Abstract: A quinone compound represented by formula (1) or (2) below: 1

Abstract: This invention provides a novel class of vitamin D related compounds, namely, the 2-alkyl-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis.

Abstract: A compound having general formula (I) in which R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of —O and —N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl. In addition to providing the compounds of formula (I), the present invention provides methods wherein the compounds of formula (I) are advantageously used, inter alia.

Abstract: Described are new, unsaturated 14,15-cyclopropano-androstanes of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are characterized by hormonal (gestagenic and/or androgenic) activity and may be used for hormone replacement therapy.

Abstract: In a process for the suspension hydrogenation of an anthraquinone compound or a mixture of two or more thereof in a reactor in which there are present the working solution in which at least one catalyst is suspended and, in addition, a hydrogen-containing gas phase, the working solution and the gas phase are, in the reactor, passed at least partly through a fitting having openings or channels whose hydraulic diameter is from 0.5 to 20 mm, preferably from 1 to 10 mm, particularly preferably from 1 to 3 mm.

Abstract: 1-Hydroxy pregnacalciferol derivatives of formula (I) and their corresponding 5,6-trans isomers wherein R1 is hydroxyl or lower alkoxy and R2 is optionally hydroxylated or lower alkoxylated lower alkynyl and R1 is C(RA) (RB)CH3 where RA is optionally hydroxylated or lower alkoxylated lower alkynyl and RB is hydroxyl or lower alkoxy or RA and RB together represent oxo and R2 is hydrogen, hydroxyl or lower alkoxy, and R3 and R4 represent hydrogen atoms, exhibit anti-progesterone activity and may be useful as antineoplastic, antifertility, antiproliferative, immunosuppressive and/or antiinflammatory agents.

Abstract: The present invention discloses compounds which are cationic cholesteryl derivatives having a nitrogen-containing ring structure as their polar head group. These compounds are useful for delivering biologically active substances to cells and for transfecting nucleic acids into cells.

Abstract: The invention relates to a quinone derivative of the following formula: which is capable of converting into two alkylating agents upon bioreduction. Substituents A, B, C, and D are as described herein.

Abstract: This invention describes the new 17a-fluoroalkyl steroids of general formula I 1

Abstract: Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

Abstract: The present invention relates to novel retinol derivatives having the formula (I): 1

Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed.

Abstract: A subject of the invention is the compounds of formula (I): 1

Abstract: A method is set forth for separating a sterol or sterol ester from crude tall oil comprising fractionating the crude tall oil into a residue fraction and a volatile fraction, wherein the temperature of the residue fraction does not exceed about 290° C., and wherein the residue fraction includes the sterol or sterol ester. By application of this method, which can be implemented in existing fractionating equipment or in specially designed pitch collecting apparatuses disclosed herein, the yield of sterols can exceed 50% with respect to the sterols present in crude tall oil. A method is also provided for separating unsaponifiable material from a tall oil stream comprising saponifying the stream with a mixture of sodium hydroxide and potassium hydroxide to form sodium and potassium salts of fatty acids, rosin acids, or both; evaporating the unsaponifiable material; and acidulating the unevaporated sodium and potassium salts.

Abstract: A process for the production of vitamin D3 or previtamin D3 from an isomer mixture comprises carrying out a separation by column chromatography using supercritical or liquid carbon dioxide, optionally with a modifier, as the mobile phase and an optionally modified silica gel as the stationary phase.

Abstract: A chromogenic receptor comprises a self-assembled chromogenic compound having at least one intrinsic binding site. The chromogenic compound is characterized by the property of producing a reversible color change responsive to binding a target substrate to the receptor. The chromogenic compound has a transition metal ion and at least one ligand bound to the transition metal ion. The ligand is selected from the group consisting of substituted phenanthroline, substituted 2,2'-bipyridine and substituted 2,2':6',2"-terpyridine. The transition metal is selected from the group consisting of Cu(I), Cu(II), Ag(I), Ni(II), Fe(II), Fe(III), Ru(II), Co(III), and Os(II). Self-assembly can be effected in the presence of Cu(I) to form receptors for dicarboxylic acids, carbohydrate, amino acids, steroids and pyrophosphates. The receptors are characterized by the formation of a 2:1 complex of the target substrate with the receptor producing a visible color change from orange to red and a measurable change in its luminescence.

Abstract: Novel substituted steroid compounds are disclosed which are more effective than known radical-trapping agents in methods of prophylaxis and therapy of radical-mediated cell damage and of treatment of diseases due to radical-mediated cell damage. The novel substituted steroid compounds can be made from steroids having an estrane, androstane, pregnane or cholestane basic skeleton and have a radical-attracting aromatic substituent of the general formula --(CH.sub.2).sub.n X, or .dbd.CH--(CH.sub.2).sub.m X at the 17 or 6 position of the steroid nucleus, wherein X=Y, OY, SY, SeY or NHY; n=0 to 5; m=n-1 and Y is a phenyl group having five substituents A, B, C, D and E, wherein A to E is independently H, alkyl, Oalkyl, Oacyl, OH, or one of the substituents B, C or D is NR.sub.2 wherein R=alkyl and each of the other substituents is hydrogen. Pharmaceutical compositions containing the novel substituted steroid compounds and methods of making them are also part of the invention.

Abstract: Invented are compositions of competitive and uncompetitive inhibitors of steroid 5-.alpha.-reductase, pharmaceutical compositions containing the compositions of inhibitors and methods of using these compositions to inhibit steroid 5-.alpha.-reductase. Also invented in the method of co-administating a 5-.alpha.-reductase inhibitor and further active ingredients.